The HSP90 inhibitor KW-2478 depletes the malignancy of BCR/ABL and overcomes the imatinib-resistance caused by BCR/ABL amplificationDachuan Zeng, Zhenglan Huang|Experimental Hematology and Oncology|2022Cited by 14